Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.
圣地亚哥，2025年1月6日 /PRNewswire/ -- 奥洛兹美医疗公司（纳斯达克：HALO）（"奥洛兹美"）今天宣布将于2025年1月8日星期三上午5:30（太平洋时间）/ 上午8:30（东部时间）举行投资者电话会议。
On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year financial guidance.
在电话会议上，首席执行官兼总裁Helen Torley博士和首席财务官Nicole LaBrosse将提供2024财年初步未经审计的全年度业绩以及更新的2025年和多年度财务指引。
Pre-registration of the live call can be accessed via link here: . The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials, which will be available 15 minutes before the call, please visit Halozyme.com.
可以通过链接访问现场电话会议的预注册。该电话会议还将在奥洛兹美的公司网站“投资者”部分进行现场直播网络广播，并将在会议结束后提供录音。要访问网络广播和演示材料（将在会议前15分钟提供），请访问Halozyme.com。
About Halozyme
关于奥洛兹美
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
奥洛兹美是一家生物制药公司，致力于推进颠覆性解决方案，以改善患者体验和治疗效果，适用于新兴和成熟疗法。作为ENHANZE药物输送技术的创新者，凭借专有酶rHuPH20，奥洛兹美的商业验证解决方案用于 facilitar 皮下注射药物和液体的输送，目标是以快速皮下输送和减少治疗负担来改善患者体验。奥洛兹美在九种商业产品的后市场中接触了超过800,000名患者的生命，覆盖100多个全球市场，已将其ENHANZE技术授权给领先的药品和生物技术公司，包括罗氏、武田、辉瑞、扬森、艾伯维公司、礼来、施贵宝、argenx、ViiV Healthcare、中外制药和Acumen Pharmaceuticals。
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
奥洛兹美还开发、生产和商业化药物-设备组合产品，或与合作伙伴一起，使用其先进的自动注射器技术，旨在提供商业或功能优势，如改善便利性、可靠性和耐受性，以及增强患者的舒适度和遵从性。公司有两款商业专有产品，Hylenex和XYOSTED，以及与Teva Pharmaceuticals和Idorsia Pharmaceuticals的合作商业产品和持续的产品开发项目。
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
奥洛兹美医疗总部位于加州圣地亚哥，并在新泽西州尤因和明尼苏达州明尼通卡设有办公室。明尼通卡也是其运营设施的地点。
For more information visit and connect with us on LinkedIn and Twitter.
有关更多信息，请访问并在LinkedIn和Twitter上与我们联系。
Contacts:
联系方式：
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
[email protected]
特拉姆·布伊
副总裁，投资者关系和企业沟通
609-359-3016
[email protected]
Samantha Gaspar
Teneo
212-886-9356
[email protected]
萨曼莎·加斯帕
Teneo
212-886-9356
[email protected]
SOURCE Halozyme Therapeutics, Inc.
来源：奥洛兹美医疗公司